Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about sorafenib tosylate and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):		Nexavar
FDA Approved:		Yes

Sorafenib tosylate is approved by the Food and Drug Administration (FDA) to treat advanced renal cell carcinoma (a type of kidney cancer) in adults. It is also approved to treat a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery.

Sorafenib tosylate is also being studied in the treatment of other types of cancer.

Patient Information Sheet on Sorafenib Tosylate - A lay language summary of important information about this drug that may include the following:

• FDA warnings or alerts about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This FDA patient information sheet applies only to approved uses of the medicine. However, much of the information may also apply to unapproved uses that are being studied.

FDA Approval for Sorafenib Tosylate - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Sorafenib Increases the Risk of High Blood Pressure (04/02/2008) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Sorafenib for Advanced Liver Cancer Increases Survival (06/13/2007) - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Sorafenib Delays Recurrence of Metastatic Kidney Cancer (02/07/2007) - Important clinical trial results for this drug, background information, and how the trial was done.

MedlinePlus Information on Sorafenib Tosylate - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials for Sorafenib Tosylate - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top